Compare Natera Inc. Common Stock (NTRA) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Union Pacific Corporation — how do they compare? Natera Inc. Common Stock trades at $394.16 (market cap $57.03B), while Union Pacific Corporation trades at $286.95 (market cap $167.74B). The key difference: Union Pacific Corporation is far larger — about 2.9× Natera Inc. Common Stock's market cap, and Union Pacific Corporation pays a 2.01% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Union Pacific Corporation for 105 Days on average.
| NTRA | UNP | |
|---|---|---|
Market Cap | $57.03B | $167.74B |
Volume | 1,131,157 | 1,359,371 |
Sector | Health | Industrials |
52-Week High | $425.64 | $310.62 |
52-Week Low | $179.42 | $216.37 |
Typical Hold Time | 0 Days | 105 Days |
Enterprise Value | $56.18B | $196.80B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Union Pacific (UNP) trades at $286.43, up 1.73% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 28.85% net income margin and 39.7% ROE, supported by recent earnings beats in Q1 and Q2 2026. Positive sentiment is driven by analyst upgrades, a consensus buy rating, and a $332.10 price target, alongside developments in battery-electric locomotives and the pending Norfolk Southern combination.
The outlook for UNP is favorable, with earnings growth and dividend stability offering investment appeal. Risks include merger uncertainty, fuel cost pressures, and economic cyclicality, but the company's pricing power and infrastructure advantages provide a solid foundation for long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
